2319668-87-4
Chemical Structure
Tibesaikosaponin V
Synonym(s): TKV
- CAS 番号: 2319668-87-4
- Formula:C42H68O15
- Molecular Weight:812.98
IUPAC Name: (4aS,6R,6aS,6bR,8aR,9R,10S,12aS,12bR,13R,14bS)-10-(((2R,3R,4S,5S,6R)-3,5-dihydroxy-6-methyl-4-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-6,13-dihydroxy-4a,9-bis(hydroxymethyl)-2,2,6a,6b,
InChIKey: ONZYNENDGFEXPD-NKRJZQNQSA-N
SMILES: C[C@]12C([C@@]3([H])[C@@](C([C@@H]1O)=O)(CCC(C)(C3)C)CO)=C[C@H]([C@@]4([H])[C@]2(CC[C@]5([H])[C@@]4(CC[C@@H]([C@@]5(C)CO)O[C@H]6[C@@H]([C@H]([C@H]([C@H](O6)C)O)O[C@@H]7O[C@@H]([C@H]([C@@H]([C@H]7O)O)O)CO)O)C)C)O
Biological Activity: Tibesaikosaponin V (TKV) is a triterpene diglycoside, which can be isolated from the methanol extract of the roots of Bupleurum chinense DC.. Tibesaikosaponin V inhibits lipid accumulation and triacylglycerol content occurred without cytotoxicity to adipocytes. Tibesaikosaponin V suppresses the mRNA expression of nuclear transcription factors, such as peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer binding protein α (C/EBPα). Tibesaikosaponin V inhibits 3T3-L1 preadipocyte differentiation. Tibesaikosaponin V can be used fro research of obesity and its associated metabolic disorders[1].
| 製品番号 | 製品名 | 純度 | 製品説明 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tibesaikosaponin V | Tibesaikosaponin V (TKV) is a triterpene diglycoside, which can be isolated from the methanol extract of the roots of Bupleurum chinense DC.. Tibesaikosaponin V inhibits lipid accumulation and triacylglycerol content occurred without cytotoxicity to adipocytes. Tibesaikosaponin V suppresses the mRNA expression of nuclear transcription factors, such as peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer binding protein α (C/EBPα). Tibesaikosaponin V inhibits 3T3-L1 preadipocyte differentiation. Tibesaikosaponin V can be used fro research of obesity and its associated metabolic disorders. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Keywords
